Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Photorefraction using Plusoptix Vision Screener: value, constancy, and credibility

Search Title by author or title

Session Details

Session Title: Paediatric Ophthalmology & Other Topics

Session Date/Time: Tuesday 25/09/2018 | 08:00-10:30

Paper Time: 08:06

Venue: Room A3, Podium 2

First Author: : M.Nassif EGYPT

Co Author(s): :    A. Gabr   S. Soliman                 

Abstract Details

Purpose:

To compare photorefration using Plusoptix vision screening to that of standard cycloplegic refraction, to detect variability between different observers and to detect existence of over or under estimation of the measured refractive errors.

Setting:

Aswan university , faculty of medicine , Egypt

Methods:

203 eyes of 203 children were included. Refraction was done for each child using PlusOptix photorefraction screener by two separate observers. Under effect of cyclopentolate eye drops, retinoscopic cyclorefraction was done for those under 4 years old and autorefraction cyclorefraction using autorefractometer was done for those 4 years or older.

Results:

In the present study 203 eyes were included. There was no significant difference between the two observers as regards to mean spherical equivalent (+0.52 ± 1.54 with range of -3.8 to +5.38 for the observer 1 and 0.540 ± 1.62 with range of -3.8 to +4.8 for observer 2). In all age groups, there was no significant difference between photorefraction results and the final subjective refraction as regards to mean spherical equivalent (0.540 ± 1.62 and 0.549 ± 1.62 respectively). Although, significant difference in axis of astigmatism between both (P value <0.001) were found.

Conclusions:

Compared to standard cycloplegic refraction, photorefraction using Plusoptix screener was found to be valuable and reproducible method in spite of mild underestimation of higher refractive errors in children.

Financial Disclosure:

-

Back to previous